Background: A recent phase III trial showed that the addition of bevacizumab, a monoclonal antibody to vascular endothelial growth factor-A, to fi rst-line irinotecan, 5-fl uorouracil, and leucovorin (IFL) prolonged median survival in patients with metastatic colorectal cancer. We carried out a retrospective analysis of patients in the trial to evaluate whether mutation status of k-ras, b-raf, or p53 or P53 expression could predict which patients were more likely to respond to bevacizumab. Methods: Microdissected tumors from 295 patients (274 primary tumors, 21 metastases) were subject to DNA sequence analysis to identify mutations in k-ras, b-raf, and p53. Nuclear P53 expression was determined by immunohistochemistry. Hazard ratios and 95% confi dence intervals (CI) for overall survival were estimated using Cox regression analysis. Results: In all biomarker subgroups, estimated hazard ratios for risk of death were less than 1 for bevacizumab- 
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Recently, the addition of bevacizumab to a combination regimen of irinotecan, 5-fl uorouracil, and leucovorin (IFL) was shown to meaningfully prolong the median survival in patients with metastatic colorectal cancer compared with that of patients who received the combination IFL regimen alone ( 4 ) . The fi ndings from this phase III bevacizumab trial were considered pivotal for the treatment of metastatic colorectal cancer. Although this result demonstrates the general potential effi cacy of antiangiogenic therapy, the identifi cation of biomarkers that may predict which patients are most likely to respond to such treatment is of considerable interest.
Potential biomarkers include mutations in k-ras and b-raf, which result in constitutive signaling through the oncogenic Ras/ Raf/Mek/Erk pathway ( 5 , 6 ) . Patients carrying tumors with k-ras mutations have been reported to have a poorer prognosis and a diminished response to adjuvant chemotherapy ( 7 -14 ) . Ras/Raf/ Mek/Erk pathway signaling has also been reported to increase expression of VEGF ( 15 -17 ) and repress negative regulators of angiogenesis ( 18 ) , suggesting that aberrations in k-ras and/or b-raf may infl uence the response to antiangiogenic therapy.
The p53 tumor suppressor gene is also frequently altered in colorectal cancer. Between 30% and 70% of colorectal malignancies have been reported to carry either a mutation in p53 and/or loss of heterozygosity at chromosome 17p, where p53 is located ( 5 , 19 , 20 ) . p53-null animal models have been shown to be resistant to cytotoxic chemotherapy ( 21 , 22 ) and less responsive than wild-type p53 models to antiangiogenic therapy ( 23 ) . Moreover, P53 dysfunction has also been associated with increased expression of VEGF ( 24 , 25 ) and decreased expression of negative regulators of angiogenesis ( 26 ) . In addition, p53 mutations and/or nuclear P53 expression have been found to have prognostic signifi cance, both independently and in conjunction with assessments of k-ras status ( 7 , 10 , 11 , 27 ) .
These preclinical and clinical data indicate that mutations in the Ras/Raf/Mek/Erk pathway or inactivation of P53 may modify the effi cacy of anti-VEGF therapies. Therefore, we investigated whether mutations in k-ras, b-raf, or p53 or P53 overexpression could identify patients with metastatic colorectal cancer who are more likely to respond to bevacizumab in terms of overall survival. A secondary aim was to explore the reported prognostic impact of these biomarkers, defi ned in terms of overall survival, irrespective of treatment received. For this study, we analyzed data on patients who had participated in the phase III trial of bevacizumab plus IFL for metastatic colorectal cancer ( 4 ) .
S UBJECTS AND M ETHODS

Patients and Study Design
Patient recruitment and trial design have been described elsewhere ( 4 ) . Briefl y, previously untreated patients with metastatic colorectal cancer were randomly assigned to three arms: IFL with placebo, IFL with bevacizumab, or 5-fl uorouracil and leucovorin with bevacizumab. At the time of enrollment, written informed consent was obtained from trial participants to permit research on their archived tissue. Survival analyses were restricted to tumor samples from patients in the treatment arms that received placebo plus IFL ( n = 411) or bevacizumab plus IFL ( n = 402).
Tissue Samples and Tissue Microarray Construction
Formalin-fi xed, paraffi n-embedded colorectal cancer tissue blocks and corresponding pathology reports were obtained for 295 of the 813 patients who participated in the bevacizumab trial from multiple centers. These samples included 21 metastases (one peritoneal, three omental, three lymph node, three lung, nine liver, and two ovarian) and 274 primary tumors. Tissue microarrays (TMAs) were assembled as described previously ( 28 ) . Core sampling was completed in triplicate to ensure that representative data were captured from the parent block ( 29 ) . Verifi cation of histology was carried out on the fi rst section cut from each array by hematoxylin and eosin (H&E) staining. Sequencing and immunohistochemistry were performed as described below on TMAs for 240 patients and on whole sections for an additional 55 patients for whom tissue blocks were not available from the primary treatment centers.
Laser Capture Microdissection and Direct Sequencing of PCR Products
TMAs and whole tissue sections were deparaffi nized and stained with H&E. Between 100 and 1000 neoplastic cells were microdissected (PixCell II; Arcturus, Mountain View, CA) from each of the 295 tumor samples. Genomic DNA from the microdissected cells was extracted into a 20 μ L volume using the Picopure DNA kit (Arcturus) according to the manufacturer's instructions. Exon 2 (coding exon 1) of k-ras (GenBank accession number L00045 ), exon 15 of b-raf (AC006344), and exons 5, 6, 7, and 8 of p53 (X54156) were amplifi ed using external primers specifi c for intronic sequences fl anking each exon ( Table 1 ) . Internal nested primers contained 5 ′ M13 forward and reverse sequences to facilitate direct sequencing of polymerase chain reaction (PCR) products ( Table 1 ) . PCR products were amplifi ed by adding 1 μ L of digested DNA to a 50 μ L reaction containing 0.5 μ M concentrations of each external primer, 0.2 μ M concentrations of each dNTP, 1.5 m M MgCl 2, and 1.5 U of a taq/pwo blend (Expand High Fidelity PCR system; Roche Molecular Biochemicals, Indianapolis, IN). Thermocycling was conducted as follows: hot-start at 94 °C for 5 minutes; 35 cycles of 94 °C for 30 seconds, 55 °C for 30 seconds, and 72 °C for 1 minute; and a fi nal extension at 72 °C for 8 minutes. One microliter of the fi rst-round PCR reaction was then added to a second-round reaction containing internal primers, which was then cycled 30 times under the same conditions. The presence of an appropriate PCR product was confi rmed by agarose gel electrophoresis. Amplicons were purifi ed using the QIAquick PCR Purifi cation kit (Qiagen, Valencia, CA) and sequenced bidirection ally using fl uorescent dye-terminator chemistry (Applied Biosystems, Foster City, CA). Sequencing reaction products were resolved with an ABI 3700 DNA analyzer (Applied Biosystems). Mutations were identifi ed by visual analysis of the sequencing chromatograms using Sequencher 4.1.4 (GeneCodes, Ann Arbor, MI). Missense mutations were defi ned as the presence of two overlapping peaks, both 50% greater than background. All mutations were confi rmed in both forward and reverse strands. p53 was classifi ed as wild-type only if the absence of mutations could be verifi ed in all four exons examined.
Immunohistochemistry for P53
Immunohistochemistry was performed on tissue sections as previously described ( 25 ) . In brief, antigen retrieval was carried out on formalin-fi xed paraffi n-embedded tissue sections for 20 minutes at 95 °C using Target retrieval solution (pH 6.0; DakoCytomation, Carpinteria, CA), according to the manufacturer's instructions. Immunolabeling was performed with a mouse monoclonal antibody (clone DO-7; DakoCytomation) that recognizes both mutant and wild-type forms of the protein ( 30 ) or with naive mouse immunoglobulins, both at 2.5 μ g/mL. Immunocomplexes were labeled with a biotinylated anti-mouse secondary antibody, an avidin -biotin -horseradish peroxidase complex (Vector Laboratories, Burlingame, CA), and the 3,3 ′ -diaminobenzidine chromogen. Tumors were scored as being positive for overexpression if nuclear staining was evident in at least 10% of neoplastic cells, consistent with other published analyses ( 31 ) .
Statistical Analysis
Mutation screening and scoring of immunohistochemistry were performed by investigators who were blinded to clinical outcome. Median survival times within each biomarker subgroup were estimated from Kaplan -Meier curves. Corresponding hazard ratios for overall survival were estimated using Cox regression analysis. Differences between subgroups were assessed by the unadjusted log-rank test. The proportional hazards assumption for the Cox model was assessed by time-dependent covariate analysis. The time-dependent covariate was not statistically signifi cant in these models, suggesting that the proportional hazards assumption is reasonable. Statistical associations between categorical variables were assessed using the chi-square test, and absolute agreement was measured by the κ statistic. P values less than .05 were considered to be statistically signifi cant. All statistical tests were two-sided.
R ESULTS
Study Group Characteristics
Patients included in these subset analyses had demographic and pathologic characteristics that were representative of the total patient population in the bevacizumab trial ( Table 2 ) . At the time of this analysis, outcome data were available for 267 of the 295 patients for whom tumor samples were examined (33% of the original trial participants). The remaining 28 patients had been treated with 5-fl uorouracil, leucovorin, and bevacizumab (arm three of the phase III trial) and were excluded from analyses of survival. Hazard ratios for death for patients in the bevacizumab arm versus the placebo arm were not statistically signifi cantly different in the subset of 267 patients compared with those for the overall trial population (0.57 versus 0.66, P = .34).
Sequencing and Immunohistochemistry Frequency Data
We obtained informative sequence data on k-ras, b-raf, and p53 mutation status for 255, 250, and 227 of the 295 tumor samples, respectively. Results were not available for the remaining tumors owing to technical problems with DNA extraction, PCR amplifi cation, or sequencing. Mutations in k-ras were identifi ed in 88 of 255 tumor samples (35%), and mutations in b-raf were identifi ed in 14 of 250 tumor samples (5.6%). Frequencies for specifi c k-ras and b-raf mutations are detailed in Table 3 . One tumor exhibited both a G595V substitution in b-raf and a G13C substitution in k-ras; the 13 other b-raf mutation -positive tumors did not harbor a mutation in k-ras.
Mutations in p53 were observed in 154 of 227 tumors (68%), and the majority of these mutations (119, or 77%) were missense changes. Nonsynonymous mutations were identifi ed in 59 codons within the 181-codon region examined, which encodes most of the DNA binding domain ( Fig. 1 ) . Point mutations at fi ve " hot-spot " codons within conserved regions of the DNA binding domain (175, 245, 248, 273, and 282) ( 32 , 33 ) accounted for 63 (41%) of the observed point mutations ( Fig. 1 ) . Nonsense point mutations and frameshift deletions that introduced premature stop codons were identifi ed in 33 tumors (21%). The majority of nonsense point mutations (21 of 28, or 75%) were located outside conserved regions ( Fig. 1 ) . In addition, one patient exhibited a two-codon repeat insertion 3 ′ to codon 242, * The subset population represents the 33% of patients from the overall phase III trial, assessing the benefi t of the addition of bevacizumab to IFL, who submitted tissue samples for biomarker research and were assessed in this study. IFL = irinotecan, 5-fl uorouracil, and leucovorin; HR = hazard ratio; CI = confi dence interval.
† Not statistically signifi cantly different. P = .34.
and another patient exhibited an 18-base pair deletion starting at codon 176.
Informative immunohistochemical results were obtained for 294 of the 295 tumor samples, of which 211 (72%) exhibited P53 overexpression. The relationship between P53 overexpression and the type of p53 mutation is illustrated in Table 4 . P53 overexpression was statistically signifi cantly associated with the presence of a p53 mutation ( P = .003), but absolute agreement between sequence and immunohistochemical results was low ( κ = 0.21). The positive and negative predictive values ( 34 ) of immunohistochemistry for sequencing data were 0.74 and 0.47, respectively. Thirty-one tumors did not overexpress P53 as measured by immunohistochemistry but did contain a mutation in the p53 gene. Of these, 23 contained nonsense mutations or frameshifts that reduced protein expression. Three of 10 tumors that exhibited P53 overexpression and nonsense/ frameshift mutations also exhibited concomitant missense mutations.
Mutations in p53 were less frequent in mucinous tumors than in nonmucinous tumors (46% versus 71%, P <.02) and more frequent in tumors distal to the splenic fl exure than in tumors proximal to the splenic fl exure (72% versus 58%, P = .05). There were no other statistically signifi cant associations between clinicopathologic variables and molecular characteristics (data not shown). Mutations in k-ras or b-raf were not associated with p53 mutation or P53 overexpression (data not shown).
Overall Survival by Treatment Arm and Biomarker Status
In all four biomarker subgroups (k-ras, b-raf, and p53 sequencing and P53 expression), estimated hazard ratios for death were less than 1 for patients treated with bevacizumab plus IFL as compared with those for patients treated with placebo plus IFL ( Fig. 2 ) . No differential benefi t from exposure to bevacizumab ( Fig. 2 ) was observed by biomarker. Similar results were found for progression-free survival and objective response rate when assessed by biomarker subgroup (data not shown).
When k-ras and b-raf mutation status were included in the Cox model of overall survival, patients whose tumors had wildtype k-ras and b-raf had better prognoses than those with mutations in one or both genes irrespective of the treatment group assessed. In patients treated with IFL and bevacizumab, the hazard ratio for death among patients with tumors containing wild-type k-ras and b-raf relative to patients with tumors containing mutations in k-ras and/or b-raf was 0.51 (95% confi dence intervals [CI] = 0.28 to 0.95), whereas in patients treated with IFL and placebo it was 0.66 (95% CI = 0.37 to 1.18) ( Fig. 2 ) . In a Cox model that adjusted for treatment, patients whose tumors contained wild-type k-ras and wild-type b-raf had a statistically signifi cantly longer median survival (HR = 0.59, 95% CI = 0.39 to 0.89, P = .01) than patients whose tumors contained mutations in one or both genes. The hazard ratio for death among patients with tumors containing wild-type b-raf relative to patients with tumors containing mutations in b-raf was considerably lower than the hazard ratio for death among patients with tumors containing wild-type k-ras relative to patients with tumors containing mutations in k-ras. However, the low frequency of b-raf mutations limits the interpretation of these fi ndings. Neither mutation status of p53 nor P53 overexpression was observed to be a prognostic factor ( Fig. 2 ) . Again, results from progressionfree survival and objective response rate analyses were similar to those for overall survival (data not shown). 167 (74) 59 (26) 226 * Two of the nine had concomitant missense mutations. † One tumor overexpressed P53 and had a concomitant missense mutation. 
D ISCUSSION
Data from clinical and preclinical research had indicated that alterations in the Ras/Raf/Mek/Erk pathway or inactivation of the p53 tumor suppressor gene may have clinical relevance to the effi cacy of anti-VEGF therapies ( 15 -18 , 23 , 24 , 26 ) , such as bevacizumab. However, in this retrospective series we did not identify any subgroup of metastatic colorectal cancer patients who were more likely to respond to bevacizumab therapy. That is, all subgroups benefi ted from the addition of bevacizumab to IFL, regardless of the status of markers of Ras/Raf/Mek/Erk pathway activity or of p53. Although patients without mutations in the k-ras and b-raf genes demonstrated statistically signifi cant better overall survival than those with a mutation in one or both genes, this difference was observed irrespective of the treatment received.
Before this study, no clinical data existed, to our knowledge, to support or refute an effect of k-ras or b-raf mutation on the effi cacy of antiangiogenic therapy, although the associations have been studied in several preclinical models. Indeed, the tumorigenic phenotype observed after the introduction of oncogenic ras into murine embryonic stem cells has been suggested to be critically dependent on VEGF expression ( 35 ) . However, a preliminary in situ hybridization analysis of VEGF expression in our tumor series (Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero S, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H: unpublished data) could not confi rm an association between VEGF expression and k-ras mutations reported by Ikeda et al. ( 36 ) . Indeed, in vivo growth of both ras-transformed and untransformed embryonic stem cells is reduced in vegf-knockout mice ( 35 , 37 ) , suggesting that VEGF-targeting strategies are effective in limiting tumor growth, regardless of k-ras status. The results from these preclinical studies are consistent with our clinical data -that is, antiangiogenic therapies that target VEGF are effective irrespective of alterations in the Ras/Raf/Mek/Erk pathway. Fig. 2 . Forest plots illustrating hazard ratios for risk of death according to biomarker status and treatment subgroup. Median survival times in each biomarker subgroup were estimated from Kaplan -Meier curves, and hazard ratios ( circles ) and 95% confi dence intervals (CI) ( horizontal lines ) were estimated using Cox regression analysis. Differences between subgroups were assessed using the log-rank test without adjustment. Relative size of the circles indicates number of patients. A ) Hazard ratios indicate the change in median survival associated with the addition of bevacizumab to IFL relative to treatment with placebo plus IFL. Dashed vertical line indicates the hazard ratio for all subjects (0.57). B ) Hazard ratios represent the median survivals in those with no mutation (or, for P53, no overexpression) (i.e., negative) relative to those with a mutation (or P53 overexpression) (i.e., positive) in each treatment arm. Hazard ratios less than 1 (indicated by solid vertical line ) represent a longer median survival. IFL = irinotecan, 5-fl uorouracil, and leucovorin; NR = not reached.
In contrast, our fi ndings for the p53 subgroup are not entirely consistent with those reported in preclinical models. Yu et al. ( 23 ) found that xenografts established from matched p53-null and p53 wild-type cell lines both exhibited a substantial reduction in tumor volume when treated with combination antiangiogenic and cytotoxic (vinblastine) therapies compared with placebo. Although these results are broadly consistent with our fi ndings, the p53-null xenografts also showed a smaller reduction in tumor volume with vinblastine plus antiangiogenic therapy than p53 wild-type xenografts ( 23 ) ; by contrast, we did not observe a statistically signifi cant difference in the survival benefi t conferred by the addition of bevacizumab for patients with p53 mutant tumors compared with patients with p53 wild-type tumors. The discrepant fi ndings between the two studies may refl ect the fact that the simpler mouse model does not completely capture the complexity of human colorectal cancer.
We also assessed whether mutations in k-ras and/or b-raf could predict overall survival. Mutations in k-ras and b-raf are frequently mutually exclusive and are considered to be biologically equivalent for our analyses ( 6 , 38 -42 ) . In both treatment groups, colorectal cancer patients whose tumors had wild-type versions of both k-ras and b-raf had a statistically signifi cantly lower risk of death than patients who had mutations in either gene ( Fig. 2 ) . This fi nding is consistent with the RASCAL II meta-analysis, which reported that k-ras mutations, specifi cally G12V, were associated with an adverse outcome ( 14 ) . It is also consistent with the fi nding from a prospective randomized, controlled trial of adjuvant chemotherapy for colorectal cancer ( 7 ) that patients with stage III disease and wild-type k-ras responded better to therapy than patients with mutant k-ras, although the difference was not statistically signifi cant.
Similarly, our investigation did not fi nd an association between p53 mutation or P53 overexpression and the over all survival of patients with metastatic colorectal cancer. Our fi nding is consistent with the report by Samowitz et al. ( 43 ) , who examined the prognostic signifi cance of p53 mutations in 1464 cases of colorectal cancer. In univariate analyses, patients with mutant p53 had a statistically signifi cantly poorer 5-year survival than patients with wild-type p53, although the magnitude of this difference was small. In addition, it did not reach statistical signifi cance in multivariable analyses. Five randomized, controlled trials have investigated the association of P53 expression as measured by immunohistochemistry with outcomes of patients with colorectal cancer ( 7 , 31 , 44 -46 ) , but there is no consensus on the prognostic impact or predictive value of nuclear P53 overexpression. Furthermore, results of studies that have specifi cally examined late-stage colorectal cancer tumors and p53 status have been inconsistent ( 47 -51 ) .
Further biomarker analyses, including a comprehensive examination of VEGF expression, are planned for our study population. To date, few studies have assessed the potential utility of biomarkers in predicting which patients are more likely to respond to antiangiogenic therapy in the clinic. Biomarkers of interest may include those involved in activation of VEGF signaling pathways [e.g., phosphorylation of VEGF receptor 2 ( 52 ) or activation of SRC ( 53 ) ( 62 -64 ) and could potentially predict response to VEGF inhibition. Further investigations are needed to determine whether these biomarkers provide better surrogate measures of VEGF dependence and susceptibility to VEGF inhibition.
Alternatively, biomarkers that summarize the effects of all angiogenic regulators may better predict patient outcome than the analysis of a single growth factor or signal transduction pathway. For example, Willett et al. ( 65 ) have shown that the preoperative administration of bevacizumab plus radiotherapy to rectal cancer patients reduces tumor perfusion, vascular volume, numbers of circulating endothelial and bone marrow progenitor cells, and microvascular density but increases the fraction of mature vessels (refl ecting a loss of immature endothelium). In addition, clinical data ( 66 ) indicate that acute or short-term changes in tumor permeability and vascularity after administration of another antiangiogenic agent, assessed by dynamic contrast -enhanced magnetic resonance imaging, might represent biomarkers inmetastatic colorectal cancer. These clinical observations are bolstered by preclinical research related to bevacizumab ( 67 ) , which suggest that magnetic resonance imaging assessing vessel permeability and surface area may be useful to monitor patient response. However, more powerful studies are needed to determine whether such biomarkers predict response to treatment in terms of overall survival.
This study has several limitations. First, consent to use archival tissue and the provision of adequate tissue by the primary treatment centers was optional, raising the possibility that these analyses may be subject to selection bias. However, because the demographic characteristics of the substudy were representative of the overall phase III trial population, any selection bias probably had a minimal impact on the fi ndings. Second, the log-rank test was unadjusted to accommodate the small sample sizes of the subgroups. Consequently the hazard ratios may be infl uenced by imbalances in important prognostic characteristics in the subsets. Finally, these analyses were performed retrospectively on relatively small subsets of predominantly primary tumors, and inferences were then made regarding the treatment of metastatic disease. Nevertheless, the frequency, type, and distribution of k-ras and b-raf mutations in this case series were similar to those seen in other published studies ( 20 , 38 , 39 , 41 , 68 ) (Table 5) , and the associations of wild-type p53 with a proximal tumor site and mucinous-type cancers are consistent with previous reports ( 43 , 69 , 70 ) . The frequency of tumors overexpressing P53 was also similar to published observations ( 10 , 71 -75 ) , and the poor agreement between P53 protein overexpression and sequencing results in this series is a common fi nding ( 71 , 74 , 76 -80 ) . Mutations in b-raf, k-ras, and p53 are commonly acquired before metastasis and are heritable. Therefore, it is highly likely that the detection of these lesions in the primary cancer is representative of the metastatic disease. Nevertheless, the data must be considered exploratory in nature, and all fi ndings warrant independent, prospective confi rmation in a larger series.
In summary, these retrospective subset analyses on primary tumors and metastases suggest that the survival benefi t from the addition of bevacizumab to fi rst-line IFL, in the treatment of metastatic colorectal cancer, is independent of k-ras, b-raf, or p53 mutation status or P53 expression. Patients with wild-type k-ras and b-raf appear to have a better prognosis than those mutant for either gene, regardless of treatment received. These fi ndings should be confi rmed prospectively in a larger population.
